Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $30.39M fell 28.0% year over year, ahead of the -58.9% change in trailing-twelve-month operating expenses. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at +85.0% a year.

Context

  • Operating expenses amounted to 10295.5% of revenue in FY2025, down 154386.0 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -28.0% holds above the trailing-twelve-month pace of -58.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$30.39M+0.1% QoQ
Last fiscal yearDec 2025
$133.84M-59.4% YoY
LTMMar 2026
$122.59M-58.9% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.0%——
1 year-59.4%——
3-year CAGR+85.0%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
133.84M USD
Year-over-year change
-59.4%
4-year CAGR
+81.5%

Operating Expenses vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -58.9% is the lowest of 7, against a peer median of +52.5%.
  • Operating expenses amounts to 9429.8% of revenue for INBX, versus a peer median of 837.0%.
INBX Competitors
Operating Expenses for INBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$333.75M USD+278.1%+101.5%297994.6%
GENBGenerate Biomedicines, Inc.FY2025$266.96M USD+22.8%—837.0%
IMTXImmatics N.V.LTM Mar 2026€250M EUR+22.1%+17.2%670.3%
JANXJanux Therapeutics, Inc.LTM Mar 2026$168.69M USD+127.4%+30.3%780.5%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$122.59M USD-58.9%+85.0%9429.8%
ABSIAbsci CorporationLTM Mar 2026$104.36M USD+58.2%+29.3%5683.9%
TECXTectonic Therapeutic, Inc.LTM Mar 2026$93.04M USD+46.9%+36.8%—
Peer median (excluding INBX) —+52.5%+30.3%837.0%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.13M2.19M1.8M200K1.3M
Cost of Revenue2.69M110.19M1.19M2.29M2.48M
Gross Profit4.44M(107.99M)609K(2.09M)(1.18M)
Gross Margin62.3%-4926.7%33.8%-1042.5%-91.0%
Research & Development71.44M110.19M190.65M203.74M113.03M
Selling, General & Admin12.36M21.12M29.38M127.91M23.3M
Operating Expenses12.34M21.12M219.83M329.36M133.84M
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
EBITDA(75.37M)(125.82M)(206.69M)1.7B(132.54M)
EBITDA Margin-1057.8%-5739.8%-11482.9%851675.0%-10195.5%
Operating Income(76.56M)(129.12M)(219.22M)(331.45M)(135.03M)
Operating Margin-1074.6%-5890.4%-12178.9%-165724.0%-10386.5%
Interest Income5.22M16.11M11.92M10.94M7.55M
Interest Expense5.22M16.11M31.84M13.49M12.2M
Other Income / Expenses(5.2M)(16.11M)(20.5M)2.02B(5.03M)
Income Before Tax(81.77M)(145.22M)(239.72M)1.69B(140.05M)
Pre-Tax Margin-1147.6%-6625.1%-13318.0%843787.0%-10773.3%
Income Tax Expense2K3K3K2K2K
Net Income(81.77M)(145.23M)(241.36M)1.69B(140.06M)
Net Margin-1147.6%-6625.3%-13408.9%843786.0%-10773.5%
EPS (Basic)(2.15)(3.62)(5.12)116.58(9.04)
EPS (Diluted)(2.15)(3.62)(5.12)116.58(9.04)
Weighted Avg Shares38.01M40.11M47.13M14.48M15.49M
Weighted Avg Shares (Diluted)38.01M40.11M47.13M14.48M15.49M

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.